Novel full-length cDNA

Abstract

Novel full-length cDNAs are provided. 1639 cDNA derived from human have been isolated. The full-length nucleotide sequences of the cDNA and amino acid sequences encoded by the nucleotide sequences have been determined. Because the cDNA of the present invention are full-length and contain the translation start site, they provide information useful for analyzing the functions of the polypeptide.

1 . A polynucleotide selected from the group consisting of the following (a) to (g): 
 (a) a polynucleotide comprising a protein-coding region of the nucleotide sequence of any one of SEQ ID NOs: 1 to 1639;    (b) a polynucleotide encoding a polypeptide comprising the amino acid sequence of any one of SEQ ID NOs: 1640 to 3278;    (c) a polynucleotide comprising a nucleotide sequence encoding a polypeptide comprising the amino acid sequence of any one of SEQ ID NOs: 1640 to 3278, wherein, in said amino acid sequence, one or more amino acids have been substituted, deleted, inserted, and/or added, and wherein said nucleotide sequence encodes a polypeptide functionally equivalent to a polypeptide comprising the selected amino acid sequence;    (d) a polynucleotide hybridizing to a polynucleotide comprising the nucleotide sequence of any one of SEQ ID NOs: 1 to 1639, wherein said nucleotide sequence encodes a polypeptide functionally equivalent to a polypeptide encoded by the selected nucleotide sequence;    (e) a polynucleotide comprising a nucleotide sequence encoding a partial amino acid sequence of a polypeptide encoded by the polynucleotide according to any one of (a) to (d);    (f) a polynucleotide comprising a nucleotide sequence having at least 70% identity to the nucleotide sequence of any one of SEQ ID NOs: 1 to 1639; and    (g) a polynucleotide comprising a nucleotide sequence having at least 90% identity to the nucleotide sequence of any one of SEQ ID NOs: 1 to 1639.    
     
     
         2 . A polypeptide encoded by the polynucleotide of  claim 1 , or a partial peptide thereof.  
     
     
         3 . An antibody binding to the polypeptide or the peptide of  claim 2 .  
     
     
         4 . A method for immunologically assaying the polypeptide or the peptide of  claim 2 , said method comprising the steps of contacting the polypeptide or the peptide of  claim 2  with an antibody binding to the polypeptide of  claim 2 , and observing the binding between the two.  
     
     
         5 . A vector comprising the polynucleotide of  claim 1 .  
     
     
         6 . A transformant carrying the polynucleotide of  claim 1 .  
     
     
         7 . A transformant carrying the polynucleotide of  claim 1 .  
     
     
         8 . A method for producing a polypeptide, said method comprising the steps of culturing the transformant of  claim 7  and recovering an expression product.  
     
     
         9 . An oligonucleotide comprising at least 15 nucleotides, said oligonucleotide comprising a nucleotide sequence complementary to the nucleotide sequence of any one of SEQ ID NOs: 1 to 1639 or to a complementary strand thereof.  
     
     
         10 . A method for synthesizing a polypeptide, said method comprising utilizing the oligonucleotide of  claim 9 .  
     
     
         11 . A method for detecting a polypeptide, said method comprising utilizing the oligonucleotide of  claim 9 .  
     
     
         12 . An antisense polynucleotide against the polynucleotide of  claim 1  or a part thereof.  
     
     
         13 . A method for detecting a polypeptide, said method comprising the following steps of: 
 a) incubating a target polynucleotide with the oligonucleotide of  claim 9  under hybridizable conditions, and    b) detecting hybridization of the target polynucleotide with the oligonucleotide of  claim 9 .    
     
     
         14 . A database of polynucleotides and/or polypeptides, said database comprising information on at least one of the nucleotide sequences of SEQ ID NOs: 1 to 1639 and/or on at least one of the amino acid sequences of SEQ ID NOs: 1640 to 3278.